The recently developed GMPF-siIDO possesses multiple advantages: tumor-specific targeting via the FA moiety, siRNA-based IDO gene knockdown, and GNR-induced photothermal tumor-killing effects. This evidence concerns the gene IDO1 and neoplasm.